معرفی
Lu Tian is a Professor of Biomedical Data Science in the School of Medicine at Stanford University, with a courtesy appointment as Professor of Statistics. He has been at Stanford since 2008, progressing from Assistant Professor to his current full Professor position in the Department of Biomedical Data Science.
- Sc.D. in Biostatistics, Harvard University (1998-2002)
- M.S. in Mathematics, Nankai University, Tianjin, P.R. China (1995-1998)
- B.S. in Mathematics, Nankai University, Tianjin, P.R. China (1991-1995)
Professor Tian's research spans several critical areas in biostatistics and data science. His work focuses on developing innovative statistical methodologies with direct clinical applications. He has made significant contributions to survival analysis, particularly in restricted mean survival time methods, which offer clinically interpretable alternatives to traditional hazard ratios in clinical trials. His research in meta-analysis addresses limitations of existing methods, especially for studies with sparse data or few studies. In personalized medicine, he develops statistical frameworks for identifying patient subgroups that benefit most from specific treatments.
His recent publications demonstrate a clear trend toward developing statistically rigorous methods with direct clinical interpretability. Rather than focusing solely on theoretical advances, his work emphasizes practical applications in oncology and cardiology clinical trials, where he develops methods that provide clear, actionable insights for clinicians. His research bridges the gap between complex statistical theory and real-world clinical decision-making, with particular emphasis on survival analysis techniques that clinicians can readily interpret and apply.
- Wangkechang Scholarship, Nankai University (1991-1998)
- Howard Hughes Fellowship (1999-2002)
- Robert B. Reed Award for Excellence in Biostatistics, Harvard (2000)
- Distinction in Teaching Award, Harvard School of Public Health (2000-2002)
Professor Tian has served as Associate Editor for several prominent journals including Biometrics, Statistics in Medicine, and Biostatistics and Epidemiology, and as Book Editor for Advanced Medical Statistics. He was a Board Director of the International Chinese Statistical Association (2015-2018). His methodological contributions have been widely adopted in clinical research, particularly his work on restricted mean survival time which has changed how treatment effects are reported in oncology trials. His development of exact inference methods for meta-analysis has provided more reliable approaches for combining evidence from small studies.
